Ropivacaine 0,2% Plus Dexamethasone Versus Ropivacaine 0,2% Plus Placebo in Modified Pectoral Block

• Status: Recruiting
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

To find out if dexamethasone used as adjuvant to ropivacaine, a long-lasting local anesthetic, prolongs the duration of modified pectoral nerve block in women undergoing breast surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University Innsbruck
• Treatments: BB 1101; Dexamethasone; Dexamethasone acetate; Ropivacaine

Criteria

Inclusion Criteria:

• female gender

• a American Society of Anesthesiologists (ASA) score of 1 or 2

• weight: body mass index (BMI) 18 - 35 kg/m2

• informed consent

• elective, unilaterale breast surgery

Exclusion Criteria:

• bleeding disorders

• any known allergy to the medication

• diabetes mellitus

• any disease that leads to alterations in the corticosteroid physiology

• drug-dependency

• BMI <18 or > 35

• systemic infections

• psychiatric diseases, that are associated with an alteration in the perception of pain

• tumor spread at the site of injection

• inflammation at the site of injection

• pregnancy